share_log

BioAffinity Technologies (NASDAQ:BIAFW) Shares Down 3%

Defense World ·  Feb 25, 2023 16:02

bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating)'s share price traded down 3% during mid-day trading on Friday . The company traded as low as $0.33 and last traded at $0.33. 101 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 5,555 shares. The stock had previously closed at $0.34.

bioAffinity Technologies Trading Down 3.0 %

The business's 50 day simple moving average is $0.41.

Get bioAffinity Technologies alerts:

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Armistice Capital LLC bought a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 204,082 shares of the company's stock, valued at approximately $72,000.

About bioAffinity Technologies

(Get Rating)

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level.

Further Reading

  • Get a free copy of the StockNews.com research report on bioAffinity Technologies (BIAFW)
  • Carvana Skidding On Revenue Decrease, Heavy Debt Burden
  • What Are Consumer Staples Stocks?
  • Is Rocky Brands Dividend A Good Fit For Your Portfolio?
  • Beyond Meat Stock Is Not Beyond Hope
  • Analysts Holding As Pfizer Waits On Two Phase 3 Studies

Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment